Speaker Details

About

John McCamant joined the Medical Technology Stock Letter as associate editor in 1987 and was named editor of this leading investment newsletter in August 2000. He has spent 25 years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, Mr. McCamant uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, and CBS Marketwatch.

Content from John McCamant

Keyword Image
Esperion: Grand Slam in Cholesterol Reduction

Esperion (ESPR) hit a grand slam with triple therapy data, submitting an NDA filing and enrollment ahead of schedule, asserts biotech expert John McCamant, editor of The Medical Technology Stock Lette…

Keyword Image
Nektar: "A Slew of Good News"

Nektar Therapeutics (NKTR) reported positive top-line Human Abuse Liability (HAL) data for NKTR-181, a drug treatment under development in the opioid sector, notes John McCamant, editor of The Medical…

Keyword Image
Intrexon: Mosquitoes & Biotech

Oxitec Ltd., a wholly-owned subsidiary of Intrexon (XON), announced that Oxitec do Brasil has signed a contract to launch the Friendly Aedes Project in Juiz de Fora, Brazil, asserts biotech expert Joh…

Keyword Image
Intrexon: Biotech, Biofuels & Fish Farming

Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter. XON’s partner Fibrocell (F…

Keyword Image
Ionis: Success in Antisense Technology

Ionis Pharmaceuticals (IONS) has a broad pipeline that continues to advance; it ANGPTL3-L has significant potential as a new and affordable cardio drug with its novel and unique mechanism of action…

Keyword Image
Sangamo: Making Gains in Gene Therapy

In a very competitive bidding process Sangamo Therapeutics (SGMO)  has inked a significant global partnership with Pfizer (PFE), who brings a wealth of value to SGMO, and notably validates the…

Keyword Image
Pacira Targets Opiod Addiction

It's "steady of she goes" at Pacira Pharmaceuticals (PCRX); overall the firm reported a steady quarter of progress with a busy event calendar ahead, notes biotech expert John McCamant, ed…

Keyword Image
Incyte: Bad News Buy?

Incyte (INCY) and their partner Eli Lilly (LLY) have received a Complete Response Letter (CRL) from the FDA delaying their approval of Bari for the treatment of rheumatoid arthritis (RA), explains Joh…

Clicky